site map
help
CordLife
International
| singapore
Investor Relations

Contact Singapore
Home / Investor Relations

Our Commitment to Shareholders

We aim to maximise long-term shareholders' value through stable and sustainable growth.

2008: A dynamic year for CordLife

CordLife delivered another stellar year of volume and revenue as a result of the management's strategic decision to rationalise the technology portfolio and focus on revenue-generating cord blood banking business in the previous year.

Growing sales and strong cash reserves place CordLife in a sound position to continue building the business during these challenging, economic times.

  1. More about CordLife.

  2. Download a copy of our latest corporate brochure here.

  3. Corporate Governance

  4. Stock Information

  5. Announcements

  6. Financial Reports

  7. Share Trading Policy

  8. Contact Us

  9. Request for Information

  10. Register for CordLife Email Alerts

Listed On ASX
Technology Pioneer
CordLife
CordLife is Singapore's first private cord blood bank, operating since 2001. CordLife operates Asia Pacific largest network of private cord blood banks with full processing and cryopreservation storage facilities in Singapore, Hong Kong, Indonesia and India as well as marketing presence throughout the region. CordLife Singapore is the first and only cord blood bank in Southeast Asia to be accredited by AABB, an international body that recognises the highest standards in cord blood banking. CordLife is also Singapore's only private cord blood bank with a successful transplant and application track record. CordLife stores stem cells only in FDA approved, multi-compartmented cryobags - providing the safest storage method - endorsed worldwide. CordLife is the first in Singapore and Hong Kong to use Sepax® fully automated cord blood processing technology to recover more cells from your baby's cord blood. The CordLife Quality Guarantee, the only such guarantee in Singapore, Hong Kong and India to assures you of a cord blood replacement or a compensation of up to US$25,000.